CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Large customer base and favourable compensation policies
4.1.2. Increasing number of diagnosed haemophilia patients
4.1.3. Growing healthcare expenditure
4.1.4. Rising R&D investments for development of haemophilia products
4.2. Market Restraints & Challenges
4.2.1. Insufficient reimbursement and high competition from established players
4.2.2. The high cost of haemophilia drugs
4.2.3. High entry barriers created by local government in certain countries
4.3. Market Opportunities
4.3.1. Growing biosimilar products
4.3.2. Rising disposable income and improving healthcare infrastructure in developing
nations
4.3.3. Patient expiry of existing brands
CHAPTER 5 GLOBAL BLEEDING DISORDERS TREATMENT MARKET – BY
TYPE
5.1. Hemophilia A
5.2. Hemophilia B
5.3. Von Willebrand Disease
5.4. Others
CHAPTER 6 GLOBAL BLEEDING DISORDERS TREATMENT MARKET – BY
DRUG CLASS
6.1. Plasma-Derived Coagulation Factor Concentrates
6.2. Recombinant Coagulation Factor Concentrates
6.3. Desmopressin
6.4. Antifibrinolytics
6.5. Fibrin sealants
6.6. Others
CHAPTER 7 GLOBAL BLEEDING DISORDERS TREATMENT MARKET - BY
GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.2.4. Costa Rica
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Chile
7.3.4. Columbia
7.3.5. Others
7.4. Europe
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Italy
7.4.5. Spain
7.4.6. Russia
7.4.7. Netherlands
7.4.8. Switzerland
7.4.9. Poland
7.4.10. Others
7.5. APAC
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. South Korea
7.5.5. Australia & New Zealand
7.5.6. Malaysia
7.5.7. Singapore
7.5.8. Others
7.6. Middle East & Africa
7.6.1. UAE
7.6.2. Saudi Arabia
7.6.3. Iran
7.6.4. Iraq
7.6.5. Qatar
7.6.6. South Africa
7.6.7. Algeria
7.6.8. Morocco
7.6.9. Nigeria
7.6.10. Egypt
7.6.11. Others
CHAPTER 8 GLOBAL BLEEDING DISORDERS TREATMENT MARKET -
COMPANY PROFILES
8.1. Baxalta Biopharmaceutical Company
8.2. Bayer AG
8.3. Novo Nordisk A/S
8.4. Pfizer Inc.
8.5. Biogen Inc.
8.6. CSL Behring Biopharmaceutical Company
8.7. Grifols, S.A.
8.8. Octapharma AG
8.9. Xenetic Biosciences, Inc.
8.10. Sanofi S.A
8.11. Janssen Global Services LLC.
8.12. Bioverativ, Inc.
8.13. Alnylam Pharmaceuticals Inc.
8.14. Bristols Myers Squibb Company
CHAPTER 9 GLOBAL BLEEDING DISORDERS TREATMENT MARKET -
COMPETITIVE LANDSCAPE
9.1. Market Share Analysis
9.2. Strategies adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 10 MARKET INSIGHTS
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
CHAPTER 11 APPENDIX
11.1. List of Tables
11.2. List of Figures
